NRIX RSI Chart
Last 7 days
6.8%
Last 30 days
1.2%
Last 90 days
62.1%
Trailing 12 Months
44.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 80.9M | 0 | 0 | 0 |
2023 | 41.7M | 60.9M | 68.6M | 77.0M |
2022 | 34.4M | 38.7M | 39.2M | 38.6M |
2021 | 20.0M | 22.9M | 29.0M | 29.8M |
2020 | 24.7M | 19.5M | 13.0M | 17.8M |
2019 | 0 | 0 | 0 | 31.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | van houte hans | sold | -44,878 | 12.826 | -3,499 | chief financial officer |
Apr 30, 2024 | van houte hans | sold | -16,702 | 12.0422 | -1,387 | chief financial officer |
Apr 30, 2024 | hansen gwenn | acquired | - | - | 5,206 | chief scientific officer |
Apr 30, 2024 | van houte hans | acquired | - | - | 4,886 | chief financial officer |
Apr 30, 2024 | ring christine | acquired | - | - | 3,924 | chief legal officer |
Apr 30, 2024 | hansen gwenn | sold | -24,168 | 12.0422 | -2,007 | chief scientific officer |
Apr 30, 2024 | ring christine | sold | -18,219 | 12.0422 | -1,513 | chief legal officer |
Feb 16, 2024 | van houte hans | sold | -68,222 | 10.0151 | -6,812 | chief financial officer |
Jan 30, 2024 | hansen gwenn | acquired | - | - | 5,207 | chief scientific officer |
Jan 30, 2024 | van houte hans | sold | -13,351 | 7.9902 | -1,671 | chief financial officer |
Which funds bought or sold NRIX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | Susquehanna Portfolio Strategies, LLC | unchanged | - | 692,772 | 2,325,060 | 0.05% |
May 07, 2024 | ClariVest Asset Management LLC | added | 0.19 | 270,044 | 902,330 | 0.09% |
May 07, 2024 | Avalon Trust Co | unchanged | - | 30,906 | 103,724 | 0.01% |
May 07, 2024 | NEW YORK STATE COMMON RETIREMENT FUND | added | 1.08 | 73,000 | 240,000 | -% |
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | reduced | -30.34 | -5,837 | 742,776 | -% |
May 07, 2024 | 49 WEALTH MANAGEMENT, LLC | reduced | -8.66 | 41,034 | 182,294 | 0.04% |
May 06, 2024 | SG Americas Securities, LLC | reduced | -16.57 | 51,000 | 326,000 | -% |
May 06, 2024 | Candriam S.C.A. | reduced | -2.83 | 3,638,690 | 13,114,000 | 0.08% |
May 03, 2024 | SIGNATUREFD, LLC | reduced | -28.97 | 82.00 | 7,100 | -% |
May 03, 2024 | GSA CAPITAL PARTNERS LLP | sold off | -100 | -249,000 | - | -% |
Unveiling Nurix Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Nurix Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.7B | 6.8B | -7.83 | 6.82 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.01 | 9.62 | ||||
BMRN | 15.5B | 2.5B | 75.6 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.2B | 107.9M | -9.48 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.3 | 9.79 | ||||
AXSM | 3.6B | 251.0M | -12.15 | 14.35 | ||||
ARWR | 3.1B | 240.7M | -10.53 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.28 | 4.35 | ||||
NVAX | 625.6M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 451.6M | 881.7K | -13.38 | 481.06 | ||||
INO | 257.1M | 4.9M | -1.9 | 52.83 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Nurix Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 9.4% | 16,585,000 | 15,159,000 | 18,467,000 | 30,676,000 | 12,685,000 | 6,783,000 | 10,791,000 | 11,432,000 | 9,621,000 | 7,396,000 | 10,252,000 | 7,091,000 | 5,011,000 | 6,689,000 | 4,085,000 | 4,182,000 | 2,864,000 | 1,862,000 | 10,580,000 | 9,439,000 | 9,234,000 |
Operating Expenses | 2.2% | 61,804,000 | 60,493,000 | 58,479,000 | 57,441,000 | 55,637,000 | 55,473,000 | 57,509,000 | 57,147,000 | 52,365,000 | 45,349,000 | 39,249,000 | 33,505,000 | 29,533,000 | 26,697,000 | 23,277,000 | 17,412,000 | 15,417,000 | - | 13,192,000 | - | - |
S&GA Expenses | 9.5% | 11,799,000 | 10,780,000 | 10,623,000 | 11,678,000 | 9,821,000 | 9,367,000 | 9,748,000 | 9,654,000 | 9,228,000 | 8,818,000 | 8,343,000 | 7,511,000 | 6,530,000 | 6,251,500 | 4,338,000 | 3,270,000 | 2,450,000 | - | 2,184,000 | - | - |
R&D Expenses | 0.6% | 50,005,000 | 49,713,000 | 47,856,000 | 45,763,000 | 45,816,000 | 46,106,000 | 47,761,000 | 47,493,000 | 43,137,000 | 36,531,000 | 30,906,000 | 25,994,000 | 23,003,000 | 20,445,500 | 18,939,000 | 14,142,000 | 12,967,000 | - | 11,008,000 | - | - |
EBITDA Margin | 5.0% | -1.68 | -1.77 | -2.50 | -2.82 | -4.14 | -4.53 | -4.25 | -3.90 | -3.85 | -3.84 | -3.33 | -3.78 | - | - | - | - | - | - | - | - | - |
Income Taxes | - | 90,000 | - | - | - | - | - | - | - | - | 44,000 | -123,000 | 139,000 | 71,000 | 53,000 | - | -20,587,000 | 11,000 | - | 10,000 | - | - |
Earnings Before Taxes | -Infinity% | -41,428,000 | - | - | - | -40,733,000 | -46,717,000 | -45,709,000 | -45,401,000 | -42,533,000 | -37,658,000 | -28,958,000 | -26,243,000 | -24,204,000 | -19,873,000 | -18,517,000 | -13,007,000 | -12,380,000 | - | -2,417,000 | - | - |
EBT Margin | 4.8% | -1.78 | -1.87 | -2.60 | -2.93 | -4.28 | -4.67 | -4.37 | -3.99 | -3.94 | -3.93 | -3.42 | -3.88 | - | - | - | - | - | - | - | - | - |
Net Income | 1.0% | -41,518,000 | -41,956,000 | -36,982,000 | -24,277,000 | -40,733,000 | -46,717,000 | -45,709,000 | -45,401,000 | -42,533,000 | -37,702,000 | -28,835,000 | -26,382,000 | -24,275,000 | -19,914,000 | -18,517,000 | 7,580,000 | -12,391,000 | -13,519,000 | -2,427,000 | -3,068,000 | -2,685,000 |
Net Income Margin | 4.3% | -1.79 | -1.87 | -2.17 | -2.58 | -4.28 | -4.67 | -4.37 | -3.99 | -3.94 | -3.94 | -3.42 | -3.89 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -286.0% | -44,835,000 | 24,104,000 | -43,592,000 | -19,549,000 | -50,729,000 | -40,520,000 | -49,726,000 | -35,703,000 | -46,102,000 | -31,773,000 | -31,837,000 | -33,626,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Assets | -12.1% | 313 | 356 | 308 | 351 | 370 | 417 | 459 | 394 | 438 | 477 | 493 | 518 | 397 | 396 | 412 | 44.00 |
Current Assets | -15.1% | 251 | 296 | 268 | 290 | 288 | 318 | 355 | 307 | 280 | 311 | 358 | 396 | 311 | 298 | 364 | 39.00 |
Cash Equivalents | -8.8% | 50.00 | 55.00 | 42.00 | 59.00 | 34.00 | 64.00 | 48.00 | 42.00 | 79.00 | 81.00 | 147 | 188 | 126 | 119 | 266 | 35.00 |
Net PPE | 6.3% | 18.00 | 17.00 | 17.00 | 18.00 | 18.00 | 17.00 | 17.00 | 16.00 | 14.00 | 11.00 | 10.00 | 8.00 | 7.00 | 7.00 | 7.00 | 4.00 |
Liabilities | -7.2% | 144 | 155 | 74.00 | 91.00 | 96.00 | 113 | 117 | 128 | 132 | 134 | 118 | 120 | 127 | 106 | 104 | 54.00 |
Current Liabilities | 0.8% | 88.00 | 87.00 | 61.00 | 72.00 | 65.00 | 71.00 | 68.00 | 73.00 | 66.00 | 66.00 | 51.00 | 47.00 | 48.00 | 45.00 | 41.00 | 16.00 |
Shareholder's Equity | -15.8% | 169 | 200 | 234 | 260 | 274 | 304 | 343 | 267 | 306 | 342 | 375 | 398 | 270 | 290 | 308 | - |
Retained Earnings | -7.6% | -586 | -545 | -503 | -466 | -442 | -401 | -354 | -308 | -263 | -220 | -183 | -154 | -127 | -103 | -83.78 | -60.46 |
Additional Paid-In Capital | 1.3% | 756 | 746 | 738 | 728 | 719 | 709 | 701 | 579 | 571 | 564 | 558 | 552 | 398 | 394 | 391 | 3.00 |
Shares Outstanding | 0.9% | 49.00 | 49.00 | 49.00 | 48.00 | 54.00 | 47.00 | 47.00 | 45.00 | 45.00 | 45.00 | 42.00 | 44.00 | - | - | - | - |
Float | - | - | - | - | 471 | - | - | - | 444 | - | - | - | 1,100 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Cashflow From Operations | -257.2% | -41,951 | 26,689 | -41,133 | -18,469 | -48,452 | -37,955 | -46,308 | -32,914 | -42,630 | -30,911 | -29,972 | -31,535 | 8,053 | -20,482 | -6,141 | -14,429 | 40,972 | - | - |
Share Based Compensation | -2.5% | 7,822 | 8,024 | 8,445 | 8,723 | 8,481 | 8,297 | 6,988 | 6,775 | 6,071 | 4,843 | 4,313 | 3,944 | 2,700 | 2,536 | 1,115 | 474 | 176 | - | - |
Cashflow From Investing | 347.1% | 35,513 | -14,373 | 22,775 | 43,831 | 16,068 | 55,008 | -63,076 | -4,765 | 40,031 | -36,523 | -12,231 | -57,110 | -2,387 | -124,563 | -108,081 | -2,336 | -19,424 | - | - |
Cashflow From Financing | 23100.0% | 1,624 | 7.00 | 1,704 | 25.00 | 1,481 | -135 | 115,407 | 432 | 1,488 | 500 | 1,552 | 150,471 | 1,359 | -1,126 | 220,420 | 119,684 | 46.00 | - | - |
Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | |
---|---|---|
Feb. 29, 2024 | Feb. 28, 2023 | |
Income Statement [Abstract] | ||
Collaboration revenue and total revenue | $ 16,585,000 | $ 12,685,000 |
Operating expenses: | ||
Research and development | 50,005,000 | 45,816,000 |
General and administrative | 11,799,000 | 9,821,000 |
Total operating expenses | 61,804,000 | 55,637,000 |
Loss from operations | (45,219,000) | (42,952,000) |
Interest and other income, net | 3,791,000 | 2,219,000 |
Loss before income taxes | (41,428,000) | (40,733,000) |
Provision for income taxes | 90,000 | 0 |
Net loss | $ (41,518,000) | $ (40,733,000) |
Net loss per share, basic (in USD per share) | $ (0.76) | $ (0.75) |
Net loss per share, diluted (in USD per share) | $ (0.76) | $ (0.75) |
Weighted-average number of shares outstanding, basic (in shares) | 54,903,407 | 54,028,238 |
Weighted-average number of shares outstanding, diluted (in shares) | 54,903,407 | 54,028,238 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Feb. 29, 2024 | Nov. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 49,813 | $ 54,627 |
Marketable securities, current | 194,180 | 233,281 |
Prepaid expenses and other current assets | 6,976 | 7,595 |
Total current assets | 250,969 | 295,503 |
Marketable securities, non‑current | 10,292 | 7,421 |
Operating lease right-of-use assets | 29,299 | 31,142 |
Property and equipment, net | 17,871 | 16,808 |
Restricted cash | 901 | 901 |
Other assets | 3,342 | 3,823 |
Total assets | 312,674 | 355,598 |
Current liabilities: | ||
Accounts payable | 5,918 | 6,401 |
Accrued expenses and other current liabilities | 28,318 | 24,970 |
Operating lease liabilities, current | 7,310 | 7,489 |
Deferred revenue, current | 46,077 | 48,098 |
Total current liabilities | 87,623 | 86,958 |
Operating lease liabilities, net of current portion | 21,846 | 23,125 |
Deferred revenue, net of current portion | 34,457 | 45,022 |
Total liabilities | 143,926 | 155,105 |
Commitments and contingencies (Note 6) | ||
Stockholdersʼ equity: | ||
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of February 29, 2024 and November 30, 2023; no shares issued and outstanding as of February 29, 2024 and November 30, 2023 | 0 | 0 |
Common stock, $0.001 par value— 500,000,000 shares authorized as of February 29, 2024 and November 30, 2023; 49,136,954 and 48,718,552 shares issued and outstanding as of February 29, 2024 and November 30, 2023, respectively | 49 | 49 |
Additional paid-in capital | 755,767 | 746,299 |
Accumulated other comprehensive loss | (350) | (655) |
Accumulated deficit | (586,718) | (545,200) |
Total stockholdersʼ equity | 168,748 | 200,493 |
Total liabilities and stockholdersʼ equity | $ 312,674 | $ 355,598 |